
Carolina Alquézar¹,²*, Estíbaliz Barrio¹*, Noemí Esteras¹,⁶*, Ana de la Encarnación¹, Fernando Bartolome³, José A. Molina⁴,⁵, and Ángeles Martín-Requero¹,²

¹Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas (CSIC), Madrid, Spain. ²Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) Madrid, Spain. ³Neuroscience Laboratory, Research Institute, Hospital 12 de Octubre, ⁴Department of Neurology, Hospital 12 de Octubre, Madrid. ⁵Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), ⁶Present address, Department of Molecular Neuroscience, UCL Institute of Neurology, London.

* These authors contributed equally to this work

Running header: Drug repositioning for Parkinson’s disease

Key words: Parkinson disease, pRb, cyclin D3/CDK6, rapamycin, SAHA, sodium butyrate

Address for correspondence:

Dr. Ángeles Martín-Requero
Centro de Investigaciones Biológicas (CSIC)
Ramiro de Maeztu 9
28040 Madrid, SPAIN
Phone: 34-91-837-3112
Fax: 34-91-536-0432
E-mail: amrequero@cib.csic.es
List of Abbreviations used:

6-OHDA: 6-hydroxy-dopamine
AD: Alzheimer’s disease
BBB: Blood brain barrier
CDK6: Cyclin-dependent kinase 6
DMEM: Dulbecco’s Modified Eagle Medium
EBV: Epstein-Barr virus
ECL: Enhanced chemiluminiscence
FBS: Fetal bovine serum
FTLD: Frontotemporal lobar degeneration
HDAC: Histone deacetylase
LCLs: Lymphoblastoid cell lines
m-TOR: Mammalian target of rapamycin
MTT: (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
NaB: Sodium butyrate
PBMCs: Peripheral Blood Mononuclear Cells
PBS: Phosphate buffered saline
PD: Parkinson’s disease
PI: Propidium iodide
pRb: Retinoblastoma protein
PVDF: Polyvinylidene difluoride
SAHA: Suberoylanilide hydroxamic acid
SDS-PAGE: Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
UPDRS: Unified Parkinson’s Disease Rating Scale
UPS: Ubiquitin proteasome system
ABSTRACT

At present, treatment for Parkinson’s disease (PD) is only symptomatic, therefore it is important to identify new targets tackling the molecular causes of the disease. We previously found that lymphoblasts from sporadic PD patients display increased activity of the cyclin D3/CDK6/pRb pathway and higher proliferation than control cells. These features were considered systemic manifestations of the disease, as aberrant activation of cell cycle is involved in neuronal apoptosis. The main goal of this work was to elucidate whether the inhibition of cyclin D3/CDK6-associated kinase activity could be useful in PD treatment. For this purpose, we investigated the effects of two histone deacetylase (HDAC) inhibitors, suberoylanilide hydroxamic acid (SAHA) and sodium butyrate (NaB), and the m-TOR inhibitor rapamycin on cell viability and cyclin D3/CDK6 activity. Moreover, the potential neuroprotective action of these drugs was evaluated in 6-hydroxy-dopamine (6-OHDA) treated dopaminergic SH-SY5Y cells and primary rat mesencephalic cultures. Here we report that both compounds normalized the proliferative activity of PD lymphoblasts and reduced the 6-OHDA-induced cell death in neuronal cells by preventing the overactivation of the cyclin D3/CDK6/pRb cascade. Considering that these drugs are already used in clinic for treatment of other diseases with good tolerance, it is plausible that they may serve as novel therapeutic drugs for PD.
INTRODUCTION

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra of the mid-brain. The clinical characteristics of PD are disabling motor abnormalities, including tremor, muscle rigidity, paucity of voluntary movements, and postural instability (Jankovic 2008). Other non-motor features like mood disorders, sleep disturbances, and cognitive impairment are also associated to PD (Chaudhuri & Schapira 2009). Approximately 90% of cases of PD are considered sporadic, being the rest determined by gene mutations. It is believed that non-genetic factors could play an important role in sporadic PD, by interacting with susceptibility genes. Age is a major risk factor for idiopathic PD. The average age at onset is 60 years and disease duration is approximately 15 years (Fan et al. 2013, Samii et al. 2004).

Current treatment strategies for PD include symptomatic treatments that consist primarily on replacing dopamine in the brain with levodopa or dopamine agonists (Djamshidian et al. 2014, Pahwa & Lyons 2014). Nevertheless, the chronic dopamine replacement therapy can cause debilitating side effects as bradykinesia. Consequently, it is important to develop new neuroprotective strategies that can help to halt or slow the progression of PD.

The cause of neuronal death in PD and other neurodegenerative disorders is largely unknown, but it appears that apoptosis is the final fate of vulnerable neurons in PD (Hajimohamadreza & Treherne 1997). Mounting evidence suggest that neuronal apoptosis is the result, at least in part, of dysregulation of cell cycle control in post-mitotic neurons (Copani et al. 2001). First of all, cell cycle-related proteins have been shown to be elevated in neurons that are at risk to die in various neurodegenerative disorders including PD (Jordan-Sciutto et al. 2003). Second, some cell cycle inhibitors appear to have neuroprotective properties in cell culture and animal models (Alvira et al. 2007, Park et al. 2000).

Work carried out in the last decade in our laboratory demonstrated the existence of cell cycle disturbances in immortalized lymphocytes from Alzheimer’s disease (AD), frontotemporal lobar degeneration (FTLD) and PD (Alquezar et al. 2012, Bartolome et al. 2009, Esteras et al. 2014). Lymphoblasts from sporadic PD were shown to have a higher proliferative activity than cells from control individuals associated with a cyclin D3/CDK6-dependent hyperphosphorylation of pRb (Esteras et al. 2014). Considering that CDKs and/or cyclins have been reported in a number of in vitro neuronal death paradigms (Katchanov et al. 2001, Osuga et al. 2000, Rashidian et al. 2005), we think that lymphoblasts, easily accessible cells, from sporadic PD patients could be a useful model to study cell cycle-related events in PD pathology, and a suitable platform to test the effects of drugs that have been proven to be useful in other diseases.
In particular, this work was undertaken to explore whether treatment with histone deacetylase (HDAC) inhibitors like sodium butyrate (NaB) or vorinostat, suberoylanilide hydroxamic acid (SAHA), which inhibit CDK6 expression levels, as well as the immunosuppressant rapamycin that downregulates cyclin D3 content, could normalize the proliferative response of PD lymphoblasts. Moreover, the potential neuroprotective action of these drugs was evaluated in well-established cell models for PD such as the 6-hydroxy-dopamine (6-OHDA)-treated dopaminergic SH-SY5Y cells and 6-OHDA-treated primary rat mesencephalic cultures. The results herein reported suggest that cyclin D3/CDK6 could be considered as a novel pharmacological target for PD, and that the repositioning of SAHA, NaB and rapamycin, drugs already licensed for different conditions, towards the treatment of PD could be a time- and cost-saving strategy.
MATERIALS AND METHODS

Materials

All components for cell culture were obtained from Invitrogen (Carlsbad, CA). L-DOPA, 6-OHDA, the HDAC inhibitors, NaB and SAHA, and rapamycin were obtained from Sigma-Aldrich. PVDF (polyvinylidene difluoride) Immobilon-P membranes for Western blots were purchased from Millipore. Rabbit anti-human antibodies, such as pRb (sc-50), CDK6 (sc-177), and mouse anti-human antibodies α-tubulin (sc-23948) and β-actin (sc-47778) were from Santa Cruz Biotechnologies. Mouse anti-human Cyclin D3 was obtained from Cell Signaling. Mouse anti-human Lamin B was from Calbiochem. The enhanced chemiluminiscence (ECL) system was from Amersham. All other reagents were of molecular grade.

Cell lines

A total of 20 patients were diagnosed in the department of Neurology of the University Hospital Doce de Octubre (Madrid, Spain) of sporadic PD following Diagnostic Criteria published elsewhere (Gelb et al. 1999). All patients were undergoing treatment with levodopa, alone or in combination with dopamine agonists (13 cases), selegiline or rasagiline (2 cases). A group of 20 age-matched individuals was used as control. The control group was formed of family members or caregivers of the PD patients, and showed a completely normal cognitive and functional level. Demographic characteristics of PD patients and control subjects are presented in Table 1. In all cases peripheral blood samples were obtained after written informed consent of the donors. All study protocols were approved by the Spanish Council of Higher Research Institutional Review Board and are in accordance with National and European Union Guidelines. Peripheral Blood Mononuclear Cells (PBMCs) were isolated on Lymphoprep™ density-gradient centrifugation according to the instructions of the manufacturer (Axix-Shield). Cells were washed twice with phosphate buffered saline (PBS), counted and resuspended at the desired concentration.

Establishment of lymphoblastoid cell lines (LCLs) was performed in our laboratory as previously described (Ibarreta et al. 1997) by infecting PBMCs with the Epstein-Barr virus (EBV). Cells were grown in suspension in T flasks in an upright position, in approximately 10 mL RPMI 1640 (Gibco, BRL) medium that contained 2 mM L-glutamine, 100 μg/mL penicillin/streptomycin and, unless otherwise stated, 10% (v/v) fetal bovine serum (FBS) and maintained in a humidified 5% CO₂ incubator at 37 ºC. Fluid was routinely changed every 3 days by removing the medium above the settled cells and replacing it with an equal volume of fresh medium.
Neuronal cell culture
Human neuroblastoma (SH-SY5Y) cells were purchased from the European Collection of Cell Cultures (Health Protection Agency, Salisbury, UK), and were propagated in Dulbecco’s Modified Eagle Medium (DMEM) containing L-glutamine (2 mM), 1% nonessential amino acids, 1% penicillin/streptomycin and 10% fetal bovine serum (FBS) under humidified 5% CO2 and 95% air. On attaining semiconfluence, cells were treated with 6-OHDA (35 μM) for 24 hours. Some cultures were pretreated for 1 hour with different compounds at several concentrations. After treatment, cultures were processed for cell viability assay or Western blotting.

Primary ventral mesencephalic cell culture
Young (3-5 months) Wistar rats were obtained from the inbred colony of the Research Institute, Hospital Doce de Octubre, Madrid, Spain. Primary mesencephalic cultures were prepared from rat embryos (E15-16) according to methods described previously with some modification (Yin et al. 2012, Pruszak et al. 2009). $1 \times 10^5$ cells were plated in pretreated poly-D-lysine-coated 96-well plates. Cells were maintained at 37°C in a 5% CO2 humidified atmosphere in Neurobasal A medium (Gibco) that contained 2 mM L-glutamine, and 10% B27® Supplement (Invitrogen). 9 days after cell culture preparation, mesencephalic cells were treated with 35 μM of 6-OHDA for 24 hours and pretreated or not for 1 hour with increasing concentrations of SAHA, NaB and rapamycin. After treatment, cultures were processed for cell viability assay (MTT). All animals were handled and cared for Council Directive 2010/63/UE of September 22, 2010.

Measurement of cell proliferation, cell viability and cell cycle
Cell proliferation was determined by total cell counting, using a TC10™ Automated Cell Counter (Bio-Rad Laboratories, Madrid, Spain). Cells failing to exclude the dye were considered nonviable. Cell viability was determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, as previously described (Denizot & Lang 1986). Cell survival was estimated as the percentage of the value of untreated controls. Cell cycle phase distribution was routinely determined by cell permeabilization followed by propidium iodide (PI) staining and flow cytometry analysis using an EPICS-XL cytofluorimeter (Coulter Científica, Móstoles, Spain).
**Immunoblotting analysis**

Whole-cell extract preparation, SDS-PAGE and Western blot analysis of lymphoblasts or neuroblastoma cells were performed as described in previous publications (Alquezar et al. 2012, Esteras et al. 2014). Primary antibodies were used at the following dilutions: 1:500 anti-pRb, 1:500 anti-cyclin D3, 1:1000 anti-CDK6, 1:1000 anti-β-actin, 1:1000 anti-α-tubulin, 1:1000 anti-Lamin B. Protein band densities were quantified using Image J software (NIH, Bethesda, Maryland, USA) after scanning the images with a GS-800 densitometer from BioRad.

**Quantitative Real-Time PCR**

Total RNA was extracted from cell cultures using Trizol™ reagent (Invitrogen). RNA yields were quantified spectrophotometrically and RNA quality was checked by the A260/A280 ratio and on a 1.2% agarose gel to observe the integrity of 18S and 28S rRNA. RNA was then treated with DNase I Amplification Grade (Invitrogen). One microgram was reverse transcribed with the Superscript III Reverse Transcriptase kit (Invitrogen). Quantitative real-time PCR was performed in triplicates using TaqMan™ Universal PCR MasterMix No Amperase UNG (Applied Biosystems) reagent according to the manufacturer’s protocol. Primers were designed using the Universal Probe Library for Human (Roche Applied Science) and used at a final concentration of 20 µM. The sequences of the forward and reverse primers used are 5’-tgatcaactaggaaaaatcttggac-3’ and 5’-ggcaacatcttgagccgagt-3’ for CDK6 and 5’-ccaccgccagaagatga-3’ and 5’-ccagagcgtagggatag-3’ for β-actin.

Real time quantitative PCR was performed in the Bio-Rad iQ5 system using a thermal profile of an initial 5-min melting step at 95ºC followed by 40 cycles at 95ºC for 10s and 60ºC for 60s.

Relative mRNA levels of the genes of interest were normalized to β-actin expression using the simplified comparative threshold cycle delta CT method \[2^{(ΔCT_{CDK6}-ΔCT_{β-actin})}\].

**Statistics**

Statistical significance was determined by the Student’s t-test or two-way analysis of variance (ANOVA) followed by Bonferroni’s test for multiple comparisons using GraphPad Prism 6 for Macintosh (La Jolla, CA, USA). A value of p<0.05 was considered significant. All the statistical data are presented as mean ± standard error of the mean (SEM).
RESULTS

Proliferative activity of control and PD lymphoblasts

Data in Fig. 1A shows proliferation of all cell lines derived from PD patients and age-matched control individuals used in this study. For these experiments, cells were seeded at an initial density of $1 \times 10^6$ cells x mL$^{-1}$ in presence of 10% FBS and counted 72 hours after serum stimulation. In agreement with previous reports (Esteras et al. 2014), lymphoblasts from PD patients showed higher rates of cell proliferation than those of control cells. To rule out an adverse effect of levodopa treatment to PD patients that could persist the immortalization procedure, we incubated a small number of lymphoblastoid cell lines from control and PD patients with L-DOPA. As shown in Fig. 1B, L-DOPA had no effect on proliferation of control and PD cells. As the enhanced proliferative activity of PD lymphoblasts was associated to the cyclin D3/CDK6-induced phosphorylation of the retinoblastoma protein (pRb) (Esteras et al. 2014), we also investigated the effect of L-DOPA addition in the cellular levels of these proteins. Fig. 1C shows, as expected, increased levels of phosphorylated pRb, CDK6, and cyclin D3 proteins of PD lymphoblasts. In addition it is shown that L-DOPA did not modify the cellular content of these proteins.

Effects of histone deacetylase inhibitors and rapamycin on cell proliferation of control and PD lymphoblasts

Bearing in mind that CDK6 has shown to be epigenetically regulated by histone deacetylases (HDAC) (Kim et al. 2007, Giessrigl et al. 2013), we considered interesting to evaluate the effects of two different HDAC inhibitors, sodium butyrate (NaB) and suberoylanilide hydroxamic acid (SAHA) on the cell response to serum stimulation. SAHA is a US Food and Drug Administration-approved drug for the treatment of cutaneous T-Lymphoma (Slingerland et al. 2014) and NaB is being evaluated in clinical trials for the treatment of shigellosis (Raqib et al. 2012) and it is thought that could be effective on the treatment of colorectal cancer (Goncalves & Martel 2013). In addition and since degradation of cyclin D3 seems to be impaired in PD lymphoblasts (Esteras et al. 2014), we investigated the influence of rapamycin, a US Food and Drug Administration-approved drug used as immunosuppressant (McAlister et al. 2002), in the proliferative response of control and PD lymphoblasts. Rapamycin was shown to downregulate cyclin D3 levels by increasing its degradation in the ubiquitin proteasome system (UPS) (Hleb et al. 2004).

To investigate the effects of these drugs on cell proliferation, lymphoblasts were incubated in the absence or in the presence of SAHA, NaB or rapamycin for 72 hours and cell viability was determined by the MTT assay. Treatment with escalating concentrations (0-2 μM) of SAHA reduced the cell viability in a dose-dependent manner (Fig. 2A left panel). Similar results were
obtained with increasing concentrations of NaB up to 50 µM (Fig. 2B left panel) or with increasing concentrations of rapamycin (Fig. 2C, left panel). Maximal effects of SAHA, NaB and rapamycin were obtained at 1 µM, 10 µM, and 30 ng/mL respectively. The proliferative activity of control and PD lymphoblasts was further assessed by total cell counting after treating cells with SAHA, NaB, or rapamycin for 72 hours. As shown in Fig. 2A-C right panels, the addition of SAHA (1 µM), NaB (10 µM) or rapamycin (30 ng/mL) abrogated the enhanced proliferative response of cells from PD patients, affecting in a lesser extent the proliferation of control cells.

Effects of SAHA, NaB and rapamycin on cell cycle status of control and PD lymphoblasts

Since the change in cell number depends on the balance between cell proliferation and cell death, we tested if SAHA, NaB or rapamycin treatment induced cell death by necrosis/apoptosis or by contrast, were able to decrease the enhanced cell proliferation observed in PD lymphoblasts. For this purpose, lymphoblasts from control and PD individuals were stained with propidium iodide (PI) and the distribution of cells in the cell cycle phases was analyzed by flow cytometry. We did not observe significant changes in the proportion of sub-G₀/G₁ hypodiploid cells, characteristic of apoptosis/necrosis, in control and PD lymphoblasts after SAHA, NaB or rapamycin treatment (Fig. 3). SAHA was more effective in decreasing the percentage of cells in S/G₂M phases than the other HDAC inhibitor NaB. Taken together, these results suggest that the decreased cell number in cultures of PD lymphoblasts in the presence of all the drugs used in this work truly reflects a decrease in cell proliferation.

Effects of SAHA, NaB and rapamycin on cyclin D3/CDK6 levels and associated kinase activity

We next evaluated the impact of SAHA, NaB and rapamycin treatment on the levels of cyclin D3 and CDK6 proteins and in their associated kinase activity, assessed indirectly by the phosphorylation status of pRb, as well as in the levels of CDK6 mRNA. In agreement with our previous work (Esteras et al. 2014), we found that the relative CDK6 mRNA levels were elevated in PD cells compared with those of control cells (Fig. 4A). As expected, both HDAC inhibitors were able to blunt the increase in CDK6 expression. At the dose used (1 µM SAHA or 10 µM NaB), they had no effect in CDK6 mRNA levels in control cells (Fig. 4A). In consonance with these results, Fig. 4B shows that these compounds were effective in restoring the normal levels of CDK6 protein and in preventing the increased phosphorylation of pRb in PD lymphoblasts. The effect of 30 ng/mL of rapamycin in decreasing the levels of cyclin D3 in control and PD lymphoblasts is shown in Fig. 4C (left panel). Consequently, the addition of rapamycin partially prevented the higher phosphorylation of the pRb protein in lymphoblasts derived from PD patients (Fig. 4C right panel).
Neuroprotective effect of SAHA, NaB and rapamycin on 6-OHDA-induced death in neuroblastoma SH-SY5Y cells and dopaminergic primary cultures

We considered interesting to validate the above-described results in lymphoblastoid cell lines by testing the effects of cyclin D3/CDK6 kinase activity-modifying drugs in two well-established neuronal models of PD, neuroblastoma SH-SY5Y cells (Ouyang & Shen 2006) and primary cultures of dopaminergic mid-brain cells (Pruszak et al. 2009). To this end, cells were pretreated for 1 hour with SAHA, NaB, or rapamycin before 6-OHDA (35 µM) exposure. Fig. 5 summarizes the effects of these drugs on 6-OHDA-treated SH-SY5Y neuroblastoma cells at the same dose used in the experiments with lymphoblasts. Fig. 5A shows that, as expected, the addition of 6-OHDA to the SH-SY5Y cells resulted in significant cell death (50%). The pre-treatment of these cells with the HDAC inhibitors or rapamycin partially prevented the cell death induced by the toxin 6-OHDA. To elucidate whether changes in cyclin D3/CDK6 activity are involved in the cell death induced by this neurotoxin, we determined the levels of both CDK6 and cyclin D3 as well as the phosphorylation status of the pRb protein in the absence and in the presence of SAHA, NaB and rapamycin. 6-OHDA induced significant increases in CDK6 and cyclin D3 proteins (Fig. 5B) and therefore in the phosphorylated form of the pRb protein (Fig. 5C). The pretreatment with SAHA, NaB or rapamycin limited the increase in these proteins caused by the addition of 6-OHDA, suggesting the involvement of cyclin D3/CDK6 in neuronal survival.

Finally, we sought to evaluate the potential neuroprotective role of these drugs in non-dividing, post-mitotic neurons as primary rat mesencephalic neuronal cultures. To this end, cells were pretreated with escalating concentrations of SAHA (0-2 µM), NaB (0-50 µM) or rapamycin (0-100 ng/mL) for 1 hour before 6-OHDA (35 µM) exposure, and cell viability was analyzed 24 hours later by MTT assay. Fig. 6 shows that the addition of 6-OHDA to the mesencephalic cells resulted in a significant cell death (40%). The pre-treatment of these cells with increasing concentrations of HDAC inhibitors (Fig. 6A) or rapamycin (Fig. 6B) partially prevented the cell death induced by the toxin 6-OHDA.
DISCUSSION

In this work, we have evaluated the effects of targeting cyclin D3/CDK6 activity on survival/death in cellular models of PD, particularly immortalized lymphocytes from sporadic PD patients, human dopaminergic SH-SY5Y neuroblastoma cells, and primary rat mid-brain cell cultures treated with 6-OHDA.

The use of peripheral cells form patients as surrogate tissue for allowing early diagnosis and more efficacious treatment for neurodegenerative disorders is widely accepted. Assuming that biomolecular defects associated with PD could be detected in any cell type, numerous studies have been carried out using peripheral cells isolated from blood (i.e. lymphocytes, monocytes, platelets, red blood cells) of PD patients (Irrcher et al. 2010, Saito et al. 2009, Zhong et al. 2006, Jakubauskiene et al. 2012). Moreover PBMCs can synthesize endogenous dopamine and express DA receptors (DA-Rs) and DA transporters (McKenna et al. 2002). Lymphoblastoid cell lines from patients can be easily obtained by infecting PBMCs with EBV. They resemble activated B cells in the expression of activation markers and adhesion molecules (Wang et al. 1990). Previous works from our laboratory demonstrated that EBV-immortalized lymphocytes respond to serum addition or withdrawal as fresh isolated lymphocytes do, and display similar changes in the content of certain proteins implicated in the regulation of proliferation and survival (Bartolome et al. 2009, Munoz et al. 2008). Taken together, these findings support the use of these lymphoblastoid cell lines for the study of disease and therapy-related modifications within ex vivo non-neural DA cells of individuals with PD. On the other hand, the human dopaminergic SH-SY5Y cell line and primary cultures of rat mid-brain neurons exposed to 6-OHDA are used commonly as in vitro models for PD, as it reflects cellular processes that occur in the degenerating dopaminergic neurons (Ouyang & Shen 2006, Kim et al. 2010).

Here, we confirmed previous data from our laboratory (Esteras et al. 2014) indicating a higher rate of proliferation of PD lymphoblasts than cells from age-matched control individuals, that was associated with increased cyclin D3/CDK6-mediated phosphorylation of the pRb protein. Activation of the pRb pathway has been reported in PD brain and in mouse models of PD (Hoglinger et al. 2007) although in neurons this leads to cell death rather than to cell division. Thus, our results support the hypothesis that unscheduled cell cycle activation underlies neurodegeneration.

Since positive regulation of CDK6 expression is achieved by HDACs (Dhar et al. 2014) and considering that inhibitors of HDACs have been theorized to be as efficacious in neurodegenerative diseases as in cancer (Harrison & Dexter 2013), we investigated whether two different HDAC inhibitors, SAHA and NaB, which are known to cross the blood brain barrier (BBB) (Barichello et al. 2014, Palmieri et al. 2009) could normalize the cell response of PD lymphoblasts. Although SAHA and NaB differ in their chemical structure (hydroxamate, or...
short chain fatty acid), they both inhibited the Zn-dependent HDACs, mainly of the class I and II. SAHA and NaB were effective in decreasing the serum-mediated increase of CDK6 levels and restored the normal rate of cell proliferation in PD lymphoblasts. These results are in line with a previous report indicating that these two broad classes of HDAC inhibitors (I and II) decreased proliferation of neural stem cells by blocking G1/S transition (Zhou et al. 2011), as well as in other normal or transformed cells (Riester et al. 2007). The concentration of SAHA (1 μM) falls within the range of the peak serum concentration achieved in patients treated with effective oral anti-tumor doses of this compound (Kelly et al. 2005). Moreover, the fact that SAHA was shown to induce changes in inflammatory markers in a mouse model of septic shock (Finkelstein et al. 2010) suggest that SAHA may have secondary beneficial effects in PD besides normalizing CDK6 levels. On the other hand, NaB has been reported to reduce degeneration of dopaminergic neurons in a mutant alpha-synuclein drosophila transgenic model of familial PD (Kontopoulos et al. 2006) and to rescue the rotenone-induced locomotor impairment and early mortality in flies (St Laurent et al. 2013), suggesting a possible benefit in the early step of PD.

Rapamycin or sirolimus is widely used to prevent transplant rejection, due to its good efficacy and reduced toxicity (Morath et al. 2007). Moreover, rapamycin has been shown to effectively inhibit the growth of several murine and human cancer (Vignot et al. 2005). The capacity of rapamycin to stimulate autophagy makes this drug attractive for neurodegenerative disorders associated with impaired organelle and protein turnover (Pignataro et al. 2011). Our results show an antiproliferative effect of rapamycin in PD lymphoblasts, which can be explained by the effects of rapamycin restoring both the increased cyclin D3 levels and its associated kinase activity.

Although PD-associated changes detected in peripheral cells from patients might not fully reflect those of PD brain, it is worth to mention that at the doses used in this work, NaB, SAHA and rapamycin were able to partially prevent the cell death induced by 6-OHDA in neuronal models of PD, as the human neuroblastoma SH-SY5Y cell line or primary rat mid-brain dopaminergic neuronal cultures. These results are in agreement with previous work reporting the effects of this neurotoxin in pRb phosphorylation (Rodriguez-Blanco et al. 2008), and add further support to the hypothesis that cell cycle alterations underlie neuronal loss. Taking together it seems that lymphoblasts from PD patients can be considered as a useful experimental model to study molecular events associated with the disease, as well as an interesting platform for testing novel therapies.

In conclusion, our data indicate that increased proliferation of PD lymphoblasts is causally linked to overactivation of cyclin D3/CDK6 complex, and that treatments aimed at blocking cyclin D3/CDK6-associated kinase activity are effective in decreasing the enhanced cell proliferation of PD lymphoblasts. The proposed scenario is represented schematically in Figure
7. NaB and SAHA, by inhibiting CDK6 protein expression, or rapamycin by decreasing the cellular levels of cyclin D3, are able to rescue the normal rates of proliferation of PD lymphoblasts.
Considering that the HDAC inhibitors as well as rapamycin are already drugs used for the treatment of several diseases with a good tolerance it seems reasonable to believe that they may hold promise as a novel treatment for PD. The repositioning of these known drugs towards PD may be therefore a time and cost-saving strategy.
ACKNOWLEDGEMENTS

This work has been supported by grants from Ministerio de Economía y Competitividad (SAF2011-28603) and Fundación Ramón Areces. We would like to thank to the Fundación Neurociencias y Envejecimiento, as well as to all patients, their families and clinicians involved in this study.

DISCLOSURE

None of the authors has any conflict to disclose

AUTHOR'S CONTRIBUTIONS

AM-R conceived and designed the experiments. JAM recruited and diagnosed the PD patients. FB generated the lymphoblastoid cell lines and helped with the neuronal cultures. CA, EB, NE and AdIE carried out the experimental work, analyzed the data, prepared the figures and performed the statistical analysis. AM-R and CA wrote the manuscript. All authors read and approved the final manuscript.
REFERENCES


**TABLE 1.**
Demographic characteristics of PD patients and healthy subjects

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Parkinson’s Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Gender (M/F)</td>
<td>4/16</td>
<td>16/4</td>
</tr>
<tr>
<td>Age study</td>
<td>63.0 ± 2.8</td>
<td>69.2 ± 2.2</td>
</tr>
<tr>
<td>Age onset</td>
<td>NA</td>
<td>64.5 ± 2.2</td>
</tr>
<tr>
<td>Hoehn and Yahr scale</td>
<td>NA</td>
<td>2.3 ± 0.2</td>
</tr>
<tr>
<td>UPDRS</td>
<td>NA</td>
<td>24.8 ± 1.6</td>
</tr>
<tr>
<td>Levodopa dosage (mg/24hours)</td>
<td>NA</td>
<td>603.3 ± 62.7</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SEM. NA not applied
FIGURE LEGENDS

Figure 1

Proliferation of lymphoblasts from control and PD patients

Control and PD lymphoblasts were seeded at an initial density of $1 \times 10^6$ cells x mL$^{-1}$ and synchronized by serum starvation for 24 hours. On that point, 10% FBS was added alone (A) or in combination with L-DOPA (100 µM) (B) and 72 hours later samples were taken and counted using a TC10™ Automated Cell Counter from BioRad. C. For Western blot analysis, cells were harvested 24 hours after L-DOPA addition and whole-cell lysates were prepared to analyze the levels of pRb, CDK6, and cyclin D3 proteins. Representative immunoblots are shown. pp = the hyperphosphorylated form of the pRb protein. Values shown represent the mean ± SEM of the quantification of the corresponding band in six independent observations carried out with different cell lines. (* p<0.05 and **p<0.01 significantly different from control cells).

Figure 2

Effects of HDAC inhibitors and rapamycin on the proliferation of lymphoblasts from control and PD patients

Immortalized lymphocytes from control and PD patients, were seeded at an initial density of $1 \times 10^6$ x mL$^{-1}$ and were incubated in medium containing 10% FBS, in the absence or in presence of increasing doses of SAHA (0-2 µM) (A left panel), NaB (0-50 µM) (B left panel) and rapamycin (0-100 ng/mL) (C left panel) for 72 hours. A total of 100,000 cells per well were seeded in a 96-well plaque for the MTT assay. Results represent the % of cell proliferation of treated cells referred to untreated ones. A, B, and C right panels. Effect of the treatment with SAHA (1 µM), NaB (10 µM), or rapamycin (30 ng/mL) on proliferation of control and PD lymphoblasts. Aliquots were taken for cell counting 72 hours after the drug administration. Data shown are the mean ± SEM of ten determinations for each drug carried out with different cell lines (* p<0.05 and **p<0.01 significantly different from control cells. †p<0.05 and ††p<0.01 significantly different from untreated cells).
Figure 3
Cell cycle distribution of lymphoblasts from control and PD patients after treatment with HDAC inhibitors or rapamycin

Immortalized lymphocytes from control and PD patients were seeded at an initial density of 1 x 10^6 x mL^-1 and cultured in RPMI medium containing 10% FBS in the absence or in the presence of the HDAC inhibitors SAHA (1 µM) and NaB (10 µM) or rapamycin (30 ng/mL). 24 hours after drugs addition, cells were harvested, fixed, and analyzed by flow cytometry as described under Methods. The percentage of cells in the different cell cycle phases is indicated for each condition.

Figure 4
Effects of SAHA, NaB and rapamycin on cyclin D3/CDK6 levels and pRb phosphorylation status

Immortalized lymphocytes from control and PD patients were seeded at an initial density of 1 x 10^6 x mL^-1, and were incubated in RPMI medium containing 10% FBS in the absence or in the presence of SAHA (1 µM), NaB (10 µM) or rapamycin (30 ng/mL). 24 hours after treatment cells were harvested to analyze CDK6 mRNA expression by quantitative RT-PCR or the levels of cyclin D3, CDK6 and pRb proteins by Western blotting. A. CDK6 mRNA expression levels after SAHA and NaB treatment. Data shown represent the mean ± SEM of different experiments carried out with five control and five PD patients. B and C. Representative immunoblots showing the effect of SAHA and NaB on CDK6 and pRb proteins or the effect of rapamycin on cyclin D3 levels and pRb phosphorylation status. pp = the hyperphosphorylated form of the pRb protein. The densitometric data represent the mean ± SEM of different experiments using all the individuals enrolled in this study (*p<0.05 and **p<0.01 significantly different from control cells; †p<0.05 and ††p<0.01 significantly different from untreated cells).
**Figure 5**

**Effects of HDAC inhibitors and rapamycin on survival and protein levels of pre-treated 6-OHDA SH-SY5Y neuroblastoma cells.**

Neuroblastoma SH-SY5Y cells were exposed to 35 µM 6-OHDA for 24 hours in the presence or in the absence of HDAC inhibitors (1 µM for SAHA and 10 µM for NaB) or rapamycin (30 ng/mL). **A.** Number of viable cells after drug treatments measured by MTT assay. Each data point represents the mean ± SEM of three replications in four different experiments. (**p< 0.01 significantly different from SH-SY5Y untreated cells; †p<0.05 and ††p<0.01 significantly different from 6-OHDA-treated cells). **B and C.** CDK6, cyclin D3 and pRb protein levels assessed by Western blotting. Representative immunoblots are shown. The densitometric data represent the mean ± SEM of four different experiments (*p<0.05 and **p<0.01 significantly different from SH-SY5Y untreated cells; †p<0.05 and ††p<0.01 significantly different from 6-OHDA-treated cells). pp = the hyperphosphorylated form of the pRb protein.

**Figure 6**

**Neuroprotective effects of HDAC inhibitors and rapamycin in 6-OHDA pre-treated mesencephalic primary cultures**

**A and B.** Primary cultures of rat mid-brain cells were exposed to 35 µM 6-OHDA for 24 hours in the presence or in the absence of different concentrations of HDAC inhibitors (0-2 µM for SAHA and 0-50 µM for NaB) (A) or rapamycin (0-100 ng/mL) (B). The number of viable cells was measured by MTT assay. Each data point represents the mean ± SEM of four replications in four different experiments. (**p< 0.01 significantly different from untreated cells; †p<0.05 and ††p<0.01 significantly different from 6-OHDA-treated cells).  

**Figure 7**

**Diagram summarizing the effects of targeting the cyclin D3/CDK6 complex in the proliferative activity of Parkinson’s disease lymphoblasts**

Lymphoblasts from PD patients show an overactivation of the cyclin D3/CDK6-associated kinase activity compared with that of control cells. Treatment of PD cells with the HDAC inhibitors NaB and SAHA or targeting the cyclin D3 degradation by rapamycin normalized the cellular content of the cyclin D3/CDK6 complex, and restored normal rates of cell proliferation.
Figure 1
Figure 2

A

![Graph showing % of cell proliferation against [SAHA] (µM). The graph compares Control and PD treatments.](image)

B

![Graph showing % of cell proliferation against [NaB] (µM). The graph compares Control and PD treatments.](image)

C

![Graph showing % of cell proliferation against [Rapamycin] (ng/mL). The graph compares Control and PD treatments.](image)
Figure 4
Figure 5
Figure 6